In Stock, Ready to Ship!
Price range: $150.00 through $500.00 — or subscribe and save 20%
99% Pure | USA Made | Multi DoseGLYCON-X™ is a synthetic dual-agonist peptide targeting GLP-1 and GIP receptors, engineered for advanced metabolic research applications. This 39- amino-acid compound is used in preclinical models to study glucose homeostasis, appetite-regulation pathways, and energy-balance mechanisms. Available in 15mg, 30mg, and 60mg lyophilized vials, GLYCON-X delivers precise dualreceptor activation for both in vitro and rodent assays. Each lot is USA-made, HPLC-verified to 99% purity, endotoxin-screened (< 0.1 EU/mg), and formulated exclusively for laboratory research.
Peptides are not ready to use. Must purchase BAC water for reconstitution.
GLYCON-X activates GLP-1 and GIP pathways simultaneously, enabling researchers to compare single versus combined incretin effects within the same assay. This dual-pathway approach provides richer mechanistic insights than single-receptor peptides.
For laboratory research use only. Not for human or animal use
In pancreatic ff-cell studies, GLYCON-X has been shown to boost insulin release, allowing researchers to map how dual-agonist peptides affect blood-sugar regulation and glucose-stimulated insulin secretion patterns. For research use only.
Not for human consumption or therapeutic application.
In rodent satiety studies, GLYCON-X reduces food-intake endpoints—making it ideal for neural-circuit mapping and behavior assays focused on appetite regulation and satiety signaling pathways. For research use only.
Not approved for human consumption or clinical use.
In adipocyte cultures, GLYCON-X has been observed to improve fat-burn markers, offering researchers a direct window into lipid-oxidation pathways and metabolic efficiency mechanisms.
This product is for laboratory research use only. Not for human or therapeutic use.
GLYCON-X engages AMPK and PPAR pathways in muscle and liver cells, helping researchers probe how cells manage fuel utilization, energy storage, and metabolic homeostasis. For research use only.
Not for human or veterinary use
Simply dissolve GLYCON-X in sterile or bacteriostatic water. Store lyophilized powder at –20°C for long-term stability. Keep reconstituted solution at 2–8°C and use within 7-14 days per protocol. GLYCON-X is not intended for human or diagnostic use.
For qualified research personnel only.
GLYCON-X™ is a novel 39-amino-acid dual-agonist designed to activate both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. In research settings, GLYCON-X enables dissection of incretin biology, allowing investigators to probe how combined receptor signaling influences insulin secretion, appetite control, and energy expenditure. The name “GLYCON-X” derives from “glycemic control”—reflecting the compound’s primary research application in glucose homeostasis and metabolic regulation studies. The “X” represents the next-generation, cutting-edge nature of this dual-agonist research tool.
Choose GLYCON-X when you need a single-molecule tool to model the interplay of GLP-1 and GIP pathways in metabolic-health research. Its dual-agonist
profile provides richer mechanistic insights than single-receptor peptides, supporting advanced studies in:
• Diabetes and glucose models — Investigate insulin secretion dynamics
and glucose homeostasis
• Obesity and weight assays — Study appetite regulation and satiety
signaling
• Cell-signaling protocols — Examine AMPK, PPAR, and incretin pathway interactions
• Pancreatic islet assays — Analyze ff-cell function and glucosestimulated insulin release
• Translational rodent protocols — Benefit from optimized pharmacokinetics
GLYCON-X stands out by combining two incretin activities—GLP-1 and GIP—into one stable molecule with optimized pharmacokinetics for research applications. Unlike separate agonists, GLYCON-X produces synergistic effects on insulin release, satiety signals, and lipid metabolism, all while maintaining a clean receptor-specific profile.
GLYCON-X is a research-grade peptide that co-activates GLP-1 and GIP receptors to study insulin release, appetite control, and energy-balance pathways in laboratory settings.
The name “GLYCON-X” derives from “glycemic control”—reflecting the compound’s primary application in glucose homeostasis research. The “X” represents its next-generation, cutting-edge formulation.
By engaging both GLP-1 and GIP receptors on pancreatic ff-cells, GLYCONX enhances glucose-stimulated insulin release through dual incretin pathway
activation.
In vitro: 50 nM–1 µM concentrations are common. In vivo rodent: 0.1– 0.5 mg/kg for dose-response and chronic-dosing studies. Always follow your laboratory’s SOPs.
GLYCON-X is available in 15mg, 30mg, and 60mg vial sizes, providing flexibility for various research protocols and budget requirements.
Yes—central and peripheral dosing protocols have demonstrated significant decreases in cumulative food-intake endpoints in rodent satiety studies.
Dissolve in sterile water for injection (SWFI) or bacteriostatic water (BAC) per your protocol. Add diluent slowly, gently swirl—do not shake—and use immediately or store appropriately.
Store lyophilized GLYCON-X at –20°C for long-term stability. Use reconstituted peptide within 7-14 days when stored at 2–8°C.
Yes—in adipocyte assays, GLYCON-X has been shown to upregulate AMPK
and PPAR pathways, modeling increased lipid oxidation and metabolic efficiency
Yes. GLYCON-X is frequently used in research stacks with compounds like MOTS-c, 5-Amino-1MQ, BPC-157, or Tesamorelin to explore synergistic metabolic effects.
Don't hestitate to contact us
End of Content.
